Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6041001 | 0.78 | ALDH1A1 (0.35) | MAPTLMNA | |
| SCHEMBL10682585 | 0.75 | CYP1A2 (0.34) | MAPTLMNACYP1A2 | |
| SCHEMBL2154033 | 0.71 | CA1 (0.41) | MAPTLMNANISCHTP53KDM4E | |
| SCHEMBL5264518 | 0.71 | KIF11 (0.39) | LMNANISCHTP53KIF11KDM4E | |
| SCHEMBL17748059 | 0.68 | — | — | |
| SCHEMBL2153842 | 0.67 | RIPK1 (0.32) | — | |
| SCHEMBL6047616 | 0.67 | AHR (0.46) | MAPTLMNANOTUMGAATP53 | |
| SCHEMBL2154215 | 0.66 | ALOX5 (0.38) | MAPTLMNANOTUMTP53CYP1A2 | |
| SCHEMBL9728 | 0.61 | MAPT (1.00) | MAPTLMNANOTUMGAATP53 | |
| SCHEMBL22591493 | 0.61 | PPARA (0.48) | MAPTLMNANISCHTP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| EP-1713778-A1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005058837-A1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | MAPT 405/4885LMNA 3210/4885NOTUM 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.